Vaxil Granted First U.S. Patent for Its Cancer Immunotherapy Antibody Platform

VAXIL BIO (TSXV: VXL), an innovative Israeli cancer research company focused on immunotherapy, is pleased to announce that it has successfully obtained a U.S. Patent for its Signal Peptide Antibody Platform known as SPmAb™.

As quoted in the press release:

“Although this marks Vaxil’s 8^th granted patent, we are pleased to finally have the first patent specifically protecting the Company’s proprietary antibody platform known as SPmAb™,” Vaxil CEO Mr. Isaac Maresky commented. “Our research and development to date has indicated that this family of antibodies possess both therapeutic and diagnostic potential for cancer patients.”

Click here to read the full press release.